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KESAN INHIBITORI TERHADAP SISTEM SITOKROM 
P450 OLEH ANDROGRAPHOLIDE DAN 14-DEOXY-11,12-
DIDEHYDROANDROGRAPHOLIDE DALAM SEL HEPG2,  
PEMBINAAN IN VITRO MODEL UNTUK INTERAKSI  
DRUG-HERBA 
 
ABSTRAK 
Penggunaan herba sebagai rawatan alternatif dan/atau rawatan tambahan 
semakin meningkat di seluruh dunia. Apabila herba digunakan bersama ubatan 
moden ia mungkin akan menyebabkan interaksi drug-herba yang serius. Kebanyakan 
interaksi drug-herba dipengaruhi oleh sistem enzim sitokrom P450 (CYP), 
terutamanya CYP1A2, CYP2D6, dan CYP3A4. Andrographis paniculata Nees 
merupakan herba tradisional yang digunakan dalam rawatan demam, malaria, dan 
penyakit kencing manis. Dengan itu, kesan andrographolide dan 14-deoxy-11,12-
didehydroandrographolide, sebatian aktif daripada A. paniculata ke atas ekspresi 
mRNA dan protein CYP1A2, CYP2D6, and CYP3A4 dalam sel HepG2 telah dikaji. 
Selepas 48 jam rawatan sel HepG2, analisis qRT-PCR dan western blot telah 
menunjukkan bahawa 20µg/mL andrographolide dan 5µg/mL 14-deoxy-11,12-
didehydroandrographolide telah mengurangkan ekspresi mRNA and protein 
CYP1A2, CYP2D6, dan CYP3A4. Rawatan konkomitan diterpenoid dan agen 
pengaruh CYP (β-naphthoflavone dan dexamethasone) juga mengurangkan ekspresi 
mRNA dan protein CYP1A2 dan CYP3A4. Kedua-dua diterpenoid telah 
merencatkan kesan aruhan β-naphthoflavone dan dexamethasone ke atas ekspresi 
CYP. Aktiviti enzim CYP3A4 juga dikurangkan oleh kedua-kedua diterpenoid 
tersebut. Kesimpulannya, penyelidikan ini telah menunjukkan bahawa kesan 
inhibitori andrographolide and 14-deoxy-11,12-didehydroandrographolide ke atas 
xv 
 
ekspresi mRNA dan protein CYP1A2, CYP2D6, dan CYP3A4 mungkin akan 
menghasilkan interaksi drug-herba sekiranya herba ini digunakan bersama dengan 
ubatan moden yang dimetabolismekan oleh enzim CYP yang sama. Pesakit dan 
profesional kesihatan perlu dinasihatkan tentang potensi interaksi drug-herba tersebut.  
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THE CYTOCHROME P450 INHIBITORY EFFECTS OF 
ANDROGRAPHOLIDE AND 14-DEOXY-11,12-
DIDEHYDROANDROGRAPHOLIDE IN HEPG2 CELLS,  
DEVELOPMENT OF A MODEL FOR IN VITRO  
STUDIES OF DRUG-HERB INTERACTIONS 
 
ABSTRACT 
The use of herbs as alternative and/or complementary therapy is increasing 
worldwide. When herbs are co-administered with modern medicine it may lead to 
drug-herb interactions that may be clinically significant. Cytochrome P450 (CYP) 
enzymes have been implicated in a large number of these preventable drug-herb 
interactions, especially CYP1A2, CYP2D6, and CYP3A4. Andrographis paniculata 
Nees is a tropical herb traditionally used for fever, malaria, and diabetes mellitus 
treatments and has an extensive ethnobotanical history in Asia. Hence, the ability of 
andrographolide and 14-deoxy-11,12-didehydroandrographolide, the most 
medicinally active compound isolated from A. paniculata to modulate the CYP1A2, 
CYP2D6, and CYP3A4 mRNA and protein expressions were examined in HepG2 
cells. After treatment of HepG2 cells for 48hr, the qRT-PCR and western blot 
analysis showed that 20µg/mL andrographolide and 5µg/mL 14-deoxy-11,12-
didehydroandrographolide resulted in significant decreased in CYP1A2, CYP2D6, 
and CYP3A4 mRNA and protein expressions respectively. Interestingly, concurrent 
treatment of diterpenoid and CYP inducer (β-naphthoflavone and dexamethasone) 
also resulted in significant decreased in CYP1A2 and CYP3A4 mRNA and protein 
expressions implicating that both diterpenoids were able to inhibit the induction 
ability of CYP1A2 and CYP3A4 inducers. As for CYP3A4, both diterpenoids also 
caused a decrease in CYP3A4 enzymatic activity. In conclusion, this study clearly 
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indicated that andrographolide and 14-deoxy-11,12-didehydroandrographolide 
inhibited the mRNA and protein expressions of CYP1A2, CYP2D6, and CYP3A4. 
Hence co-administration of this herbal preparation together with modern drugs which 
are known to be metabolized via the same CYP pathway may cause drug-herb 
interactions. Patients and healthcare professional should be advised of the possible 
drug-herb interactions.   
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INTRODUCTION 
1.1 Drug interactions 
Drug interactions refer to adverse drug reactions (ADR) produced by the 
administration of a drug or co-exposure of the drug with another substance which 
modifies the patient’s response to the drug (Shargel, 2004). When a regimen of two 
or more drugs are prescribed, drug interactions become an important consideration 
for patients and physicians (Shapiro and Shear, 1999). Non-prescription drugs, herbs 
or alternative medicine, nutrient, and foods may also be implicated in drug 
interactions leading to drug-herb interactions, drug-nutrient interactions, and drug-
food interactions respectively (Sorensen, 2002). These interactions could lead to 
therapeutic failure, adverse drug reactions, and even death.  
As of January 1, 2002, there were more than 3200 prescription drugs, 300 
dietary supplements, and 600 herbal products available in the market in the United 
States of America (USA) (Prybys, 2004). This equates to trillions of possible drug 
combinations and potential drug interactions (Prybys, 2004). Widespread use, 
especially marketing approval of modern drug, sometimes results in the discovery of 
new drug interactions. For several drugs, the late identification of drug interactions 
has led to restrictions being placed on the indications, or even withdrawal of drug 
from the market. For example, Mibefradil (Posicor®), a calcium channel blocker used 
to treat hypertension, was voluntarily withdrawn from the market early in June 1998 
because of severe drug interactions (SoRelle, 1998). Mibefradil was found to 
potently inhibit cytochrome P450 (CYP), namely CYP2D6 and CYP3A4, a major 
group of haem containing monooxygenases involved in the metabolism of 
endogenous substances (SoRelle, 1998). Cardiac shock and death was reported in a 
number of cases when mibefradil was administered with other cardiotropic drugs 
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such as calcium channel blockers and β-blockers (SoRelle, 1998). Other examples 
such as cisapride (Prepulsid®, Janssen-Ortho), astemizole (Hismanal®, Janssen-
Pharmaceutica), and terfenadine (Seldane®, Aventis) were also withdrawn from the 
USA market due to drug interactions (Dresser and Bailey, 2003).  Since specific 
diagnostic codes for drug interactions are lacking, it is difficult to obtain precise rates 
of incidence and prevalence (Shapiro and Shear, 1999).  
 
1.1.1 Drug-herb interactions 
Herbs and botanically derived therapies have been used for variety of 
ailments for thousands of years, dating to 50,000 B.C (Venkataramanan et al., 2006). 
As a matter of fact, a lot of modern drugs were actually derived from plants. For 
example, morphine which is used as a painkiller is derived from opium poppy 
(Papaver somniferum L.); digitalis used in heart medication is from foxglove 
(Digitalis purpurea), and reserpine, an antihypertensive drug, is from rauwolfia 
(Rauwolfia serpentine). According to World Health Organization (WHO), millions 
of people today use herbal therapies along with prescription and non-prescription 
medications. 70-80% of the world population especially in developing countries 
relies on traditional medicine, mostly plant drugs for their primary health care needs 
(Barrett et al., 1999, Gedif and Hahn, 2002). In 1999, the global market for herbal 
supplements exceeded US$15 billion, with US$7 billion in Europe, US$2.4 billion in 
Japan, US$2.7 billion in Asia and US$3 billion in North America (Raskin et al., 
2002). In USA, it is reported that from 1990-1997, the total visits to alternative 
medicine practitioners has increased from 427 million to 629 million  (Eisenberg et 
al., 1998). The number of visits to alternative medicine practitioners was even higher 
than the total visits to primary care physicians (Eisenberg et al., 1998).  
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In Malaysia, traditional products form the largest group of medicines that was 
registered (37.1%), as compared with prescription drugs (32.2%) and non-
prescription (over-the-counter) drugs (23.9%) (Ang, 2005). From 2000 to 2005, 
annual sales for traditional medicines in Malaysia has increased from US$ 385 
million to US$ 1.29 billion and the herbal medicines industry was expected to be 
worth US$ 2.5 billion by 2010 (Aziz and Tey, 2009). This specific industry is 
growing faster than the general economy, reported at more than 15-20% per year 
(Aziz and Tey, 2009). Such huge market size, globally and locally, had led to 
worldwide interest in the scientific validation of the therapeutic efficacy of 
traditional plant-based medicines.  
A high percentage of patients (up to 60%) using alternative therapies are 
reported to have never informed their physician of their herb use (Halsted, 2003). In 
most cases, the widespread usage of herbs by the patients are solely based on the 
basic of claims and anecdote and this is particularly worrying because herbs are often 
used concurrently with prescribed or over-the-counter medications without the 
knowledge of the pharmacists and physicians (Huang et al., 2004, Eisenberg et al., 
1998, Kaufman et al., 2002). Most patients assume "natural" products are harmless 
and not worth mentioning, or they fear being ridiculed by doctors sceptical about 
their use (Kaufman et al., 2002). There is little public understanding or appreciation 
of the fact that these “natural” herbs are actually a combination of potentially 
biologically active compounds that exist in unknown quantities. It is reported that an 
estimated 15 million adults in 1997 took prescription medications concurrently with 
herbal remedies and/or high-dose vitamins (Eisenberg et al., 1998). As such, patients 
taking prescription medications metabolized through the same pathways as the herbs 
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are at an increased risk of drug-herb interactions that could lead to therapeutic 
failure, adverse drug reactions, and even death.  
In Malaysia, the number of adverse reaction cases attributable to traditional 
medicine was reported to be 31 cases in 2007 and 26 cases in 2008 according to a 
report by the Malaysian Adverse Drug Reaction Advisory Committee (MADRAC), 
National Pharmaceutical Control Bureau, Ministry of Health 
(http://portal.bpfk.gov.my/bpfk/). However, these numbers of reported cases most 
probably do not reflect the actual frequency of adverse reactions caused by 
traditional herbal preparations as most cases go unreported. Moreover, the number of 
adverse reaction due to drug interactions was not known.  
One of the most extensively reported example for drug-herb interactions 
involved Hypericum perforatum (St. John’s wort), a popular herbal remedy for 
depression and mood disorders (Sorensen, 2002).  St. John’s wort is reported to be 
involved in a number of drug-herb interactions when consumed with cyclosporine, 
ethinyl estradiol/desogestrel, theophylline, phenprocoumon, warfarin, amitriptyline, 
indinavir, digoxin, nefazodon, sertraline, or paroxetinev causing undesired outcomes 
(Di Carlo et al., 2001).  St. John’s wort extracts activate CYP3A4 which is the most 
important of the CYP family of hepatic enzymes involved in the metabolism of many 
common drugs (Ernst, 1999, Moore et al., 2000a). Concomitant use of St John’s wort 
with drugs metabolized by CYP3A4 will bring about an accelerated clearance of 
these compounds which results in reduced efficacy.  
Given the widespread use of herbs worldwide, documented drug-herb 
interactions are sparse. In many cases, the drug-herb interactions may increase drug 
toxicity or even be fatal. Thus, as an integrated part of medical treatment, monitoring 
of adverse events when herbs are co-administered with drugs could be carried out 
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and potential drug-herb interactions could be identified. This would enable more 
accurate product labelling and provision of useful information on potential drug-herb 
interactions to medical professionals. 
 
1.2  Cytochromes P450 (CYPs)  
1.2.1  Biochemistry of cytochromes P450 
 An analysis revealed that 59% of drugs cited in adverse drug reaction (ADR) 
studies are metabolized by phase I drug-metabolizing enzymes and that CYP 
enzymes account for 80% of  phase I drug-metabolizing enzymes (Phillips et al., 
2001). Thus, understanding of drug interactions involving CYP enzymes and their 
mechanism can help to evaluate potential ADRs when herbs are prescribed 
concurrently and this will contribute to a much more effective and safe management 
of medications.      
Cytochrome P450 (CYP) enzymes are a major group of haem containing 
monooxygenases involved in the metabolism of endogenous substances, such as 
corticosteroids and fatty acids, and xenobiotics, including carcinogens and 
medications (Mansuy, 1998). CYP enzymes are a superfamily of oxidative enzymes 
with 57 different active genes encoding them (Ingelman-Sundberg, 2004). The CYP 
enzymes were first reported in 1958 from two independent researchers as an unusual 
cytochrome (Garfinkel, 1958, Klingenberg, 1958), which later became known as 
P450 due to its characteristic soret absorption maximum at 450nm in the UV 
spectrum of its carbon monoxide adduct (Omura and Sato, 1962, Omura and Sato, 
1964a, Omura and Sato, 1964b). The enzymes exist as multiple forms with different 
properties in respect of their substrate selectivity and certain physicochemical 
characteristics (Lewis, 2001). The multiplicity of forms led to the enzymes being 
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termed “mixed-function” oxidases and “monooxygenases” to describe their ability to 
insert oxygen into a large variety of substrates and wide range of structural classes of 
compounds (Kanamura and Watanabe, 2000, Porter and Coon, 1991). The CYP 
enzymes are haemoproteins that generally function in mixed-function oxidase 
reactions, using the simplified stoichiometry as shown in Figure 1.1 (Lewis, 2001). 
The CYP enzymes mixed-function oxidases catalyze a wide variety of reactions 
including epoxidations, N-dealkylations, O-dealkylations, S-oxidations, and 
hydroxylations of aliphatic and aromatic substrates (Lewis, 2001). The diversity of 
the reactions catalyzed can be understood by considering that the initial reaction in 
all cases involves insertion of a hydroxyl group into the substrate (RH) to form a 
hydroxylated intermediate (ROH) which can then, depending on the nature of the 
substrate and the stability of the intermediate, undergo phase II metabolism (Figure 
1.1). The first step involves binding of the substrate to the ferric form of the CYP 
enzyme. The second step involves transfer of one electron from the NADPH-CYP 
reductase to the iron of the ferric CYP enzyme to give a ferrous enzyme- substrate 
complex. The reduced CYP-substrate complex then binds with O2 to form a ferrous 
enzyme-O2-substrate ternary complex. The addition of a second electron to this 
tertiary complex by the reductase results in the formation of an iron peroxo- species. 
The next step involves cleavage of the oxygen-oxygen bond. One of the oxygen is 
released with the uptake of two protons, resulting in the formation of water. The 
retained oxygen remains associated with the heme iron as activated oxygen. The 
activated oxygen atom associated with the iron is then inserted into the substrate, 
resulting in a two-electron oxidation of the substrate to the alcohol.  The product is 
then released, regenerating the native ferric CYP enzyme that is available to begin 
another catalytic cycle. 
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Figure 1.1 Stoichiometry of CYP enzymes mixed-function oxidase reaction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RH + O2 + NADPH + H
+                       ROH + H2O + NADP
+ 
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All CYP enzymes, or more correctly called as heme-thiolate 
monooxygenases (Bachschmid et al., 2005), have a common characteristic of a 
conserved peptide motif, Phe – X (6-9) – Cys – X – Gly (where X denotes any amino 
acid), near the C terminus (Nebert and Dalton, 2006). An octahedral heme iron binds 
to the fifth position of the cysteine and is capable of transferring one atom of 
atmospheric oxygen into the substrate during phase I metabolism. The oxygenated 
product is then hydroxylated in phase II metabolism (Lewis, 2001).   
 
1.2.2  Nomenclature system of cytochromes P450  
Early naming system for CYP enzymes was developed based on designations 
of CYP enzyme column fractions obtained by each investigator. For example, 
CYP2D1, CYP2D2, CYP2D3, CYP2D4, and CYP2D5 of rat were named as db1, 
db2, db3, db4, and db5 respectively (Lewis, 2001). Such naming system was 
confusing because the designations of the CYP enzymes were not always unified and 
result in the presence of multiple designations for a same CYP enzyme, e.g. human 
CYP3A4 was called in different name as hPCNI, nf-25, and nf-10. A more 
systematic nomenclature system for human superfamily CYP enzymes was 
developed and periodically updated by Nebert (Nebert, 1997, Nelson et al., 1993). In 
this nomenclature system designed by Nebert, human CYP enzymes are now 
arranged into 18 families and 57 subfamilies based on their amino-acid sequence 
identity. This “new” nomenclature system makes use of the symbol CYP as an 
abbreviation of cytochrome P450, which is italicized when referring to the gene. 
Proteins that have >40% sequence similarity are members of the same gene family, 
whereas those with >70% similarity are members of the same subfamily. An 
alphanumerical designation is employed for naming P450 families, subfamilies, and 
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individual proteins as listed in Table 1.1. This CYP nomenclature system is not only 
meant to be used on classification of human CYPs but also other species CYPs such 
as rat, mouse, guinea pig, toadfish, drosophila, mosquito etc ((Lewis, 2001). Nebert’s 
CYP nomenclature system has successfully unified all the CYP enzymes designation 
and reduce confusion and enable the inter-species comparison of CYP enzymes.   
 
1.2.3  Cytochromes P450 in liver  
CYP enzymes play a huge role in metabolism process of many xenobiotics 
and endogenous substrate in the liver (Table 1.1). The CYP enzymes are highly 
conserved in all five biological kingdoms from Archebacteria to humans (Nebert et 
al., 1989), with the apparent exception of enterobacteria (Nelson et al., 1993, Nelson 
et al., 1996). It is thought that the CYP enzymes responsible for foreign compound 
metabolism evolved about 400-500 million years ago to enable animals to detoxify 
chemicals in plants (Gonzalez and Gelboin, 1994, Gonzalez and Nebert, 1990, 
Nebert, 1997). In mammalian species, CYP enzymes are present predominantly in 
the smooth endoplasmic reticulum (ER) membrane of hepatocytes in liver (Stier, 
1976). They are also expressed in most other organs and tissues such as the kidney, 
breast, prostate, skin, nasal epithelium, gonads, placenta, brain, lung, spleen, 
pancreas, and gastro-intestinal tract (Lewis, 2001). 
However, liver remains as the major site for CYPs expression and different 
human CYP isoforms vary in their abundance within liver, as shown in Table 1.2. 
CYP3As are the most abundant CYP enzymes in liver (28%), follow by CYP2Cs 
(18%), and CYP1A2 (13%) (Lewis, 2001). These three CYPs sum up for about 60% 
of all CYPs while other CYPs are only expressed in a relatively low percentage.  
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Table 1.1  Human CYP enzymes (Nebert and Dalton, 2006) 
Family Number of 
subfamilies 
Number of 
genes 
Substrates/function 
CYP1 2 3 Metabolism of xenobiotics and 
eiscosanoids 
CYP2 13 16 Metabolism of xenobiotics and 
eiscosanoids 
CYP3 1 4 Metabolism of xenobiotics and 
eiscosanoids 
CYP4 6 12 Metabolism of xenobiotics and 
eiscosanoids 
CYP5 1 1 Thromboxane A2 synthase 
CYP7 2 2 Cholesterol, bile acid synthesis 
CYP8 2 2 Prostacyclin synthase, bile acid synthesis 
CYP11 2 3 Steroidogenesis 
CYP17 1 1 Steroid 17-hydroxylase, 17/20-lyase 
CYP19 1 1 Oestrogen aromatization 
CYP20 1 1 Expressed in gastula, neural patterning and 
somitogenesis, organogenesis, fetus and 
nasopharynx. 
CYP21 1 1 Steroid 21-hydroxylase 
CYP24 1 1 Vitamin D3 24-hydroxylase 
CYP26 3 3 Retinoic acid hydroxylation 
CYP27 3 3 Bile acid biosynthesis, vitamin D3 
hydroxylations 
CYP39 1 1 24-hydroxycholesterol 7-hydroxylase 
CYP46 1 1 Cholesterol 24-hydroxylase in the central 
nervous system 
CYP51 1 1 Lanosterol 14-demethylase 
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Interestingly, the highly abundance number of certain CYP enzymes may not 
exactly explain their “real” capacity in drug metabolism in human liver. For 
example, even though CYP2D6 is only a relatively minor form, 2.5%, in human 
liver, it metabolizes up to 18.8% of all prescribed drugs as compared to CYP1A2 
enzymes (Table 1.2). The relative data given in Table 1.2 may differ among 
individuals as the expression of CYPs are generally affected by various intrinsic and 
extrinsic factors such as genetic variation, drug consumption, nutrient and diet status 
which may affect the expression of CYPs (Lewis, 2001).  
 
1.2.4 Regulation of cytochromes P450  
Four of CYP gene families (families CYPs 1–4) code for liver-expressed 
enzymes that metabolize foreign compounds (drugs, environmental chemicals, and 
other xenobiotics) and endogenous lipophilic substrates. These CYP genes are 
regulated in a variety of ways and at multiple levels: they exhibit tissue-specific 
expression, are regulated by endogenous hormones and cytokines, and respond to 
structurally diverse foreign chemicals, which often increase CYP protein levels by 
stimulating P450 gene transcription initiation and are regulated by nuclear receptors 
(NR) (Honkakoski and Negishi, 2000). The induction of CYP1 family member 
expression is regulated by a heterodimer composed of the aryl hydrocarbon receptor 
(AhR) and the aryl hydrocarbon receptor nuclear translocator (Arnt) (Fujii-Kuriyama 
and Mimura, 2005, Kawajiri and Fujii-Kuriyama, 2007) while the expression of 
CYP2, 3, and 4 family members are regulated by the nuclear receptors constitutive 
androstane receptor (CAR),  pregnane X receptor (PXR), and peroxisome 
proliferator-activated receptors (PPAR), respectively (Waxman, 1999, Karpen, 2002, 
di Masi et al., 2009). CAR, PXR, and PPAR belong to nuclear receptor (NR)  
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Table 1.2  Relative abundance of CYP isoenzymes in human liver and 
relative contribution of CYP enzymes to drug metabolism (Lewis, 
2001) 
CYP Relative abundance in 
human liver 
Relative contribution to drug 
metabolism 
1A1 < 1% 2.5% 
1A2 ~ 13% 8.2% 
1B1 < 1% Unknown 
2A6 ~ 4% 2.5% 
2B6 < 1% 3.4% 
2C8, 2C9 ~ 18% 15.8% 
2C18, 2C19 ~ 1% 8.3% 
2D6 ≤ 2.5% 18.8% 
2E1 ≤ 7% 4.1% 
2F1 < 1% 1.3% 
3A4, 3A5 ≤ 28% 34.1% 
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superfamily while AhR belong to basic helix loop helix (bHLH) family of 
transcription factors.  
 
1.2.4.1 Overview of nuclear receptors (NR) 
In humans, 49 members of the nuclear receptor (NR) family have been 
definitively cloned and identified (Robinson-Rechavi et al., 2001, Kininis and Kraus, 
2008). Members of the family share a common structure that includes a variable 
amino-terminal domain, a highly conserved central DNA binding domain (DBD) and 
a C-terminal ligand-binding domain (LBD) (Mangelsdorf et al., 1995). Typically, 
there are two transcriptional activation domains in a NR: the activation function 1 
(AF-1), which resides in the N-terminal domain and the activation function 2 (AF-2), 
which is present in the C-terminal portion of the LBD as shown in Figure 1.2 
(Mangelsdorf et al., 1995, Mangelsdorf and Evans, 1995).   
Poorly-conserved AF-1 is allocated at the N-terminus and is responsible for 
the ligand-independent transcriptional activation and involved in the coordinated 
interaction of co-activators and co-repressors (Honkakoski and Negishi, 2000). 
Immediately adjacent to AF-1 is a highly-conserved DBD which contains two zinc 
finger motifs and responsible for high-affinity recognition and binding to the 
canonical DNA hexamer sequences comprising the specific response elements (REs) 
(Mangelsdorf and Evans, 1995, Mangelsdorf et al., 1995). A small hinge region 
facilitates the three-dimensional functional organization of the multiple domains. The 
C-terminus region, AF-2, provides ligand-dependent transactivation, via a complex 
three-dimensional conformational switch to coordinate interactions with co-
regulators. The LBD serves the greatest differentiating and identifying function 
among NR family members, determining the affinity of receptors for various 
 
 
14 
 
 
Figure 1.2 Nuclear receptor domains and DNA binding elements. AF-1: 
Activation function 1; DBD: DNA binding domain; LBD: Ligand 
binding domain; AF-2: Activation function 2 (Mangelsdorf et al., 
1995, Mangelsdorf and Evans, 1995).  
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potential ligands, and is responsible for the species variability of ligand 
responsiveness (Edwards, 2000).  
The ligands for the NRs are all small and lipophilic in nature, which permits 
them to diffuse into cells (Handschin and Meyer, 2003). The binding of a ligand to 
the LBD results in a conformational change in the AF-2 that disrupts interactions 
with transcriptional co-repressor proteins such as nuclear receptor corepressor 
(NCoR) and silencing mediator for retinoid and thyroid hormone receptors (SMRT) 
and permits interactions with transcriptional coactivator proteins such as the steroid 
receptor co-regulator-1  (SRC-1) family members (Edwards, 2000). The activated 
NR stimulates the expression of target genes by binding to short DNA sequence 
motifs, termed response elements (RE), located in the regulatory regions of target 
genes. 
 
1.2.4.2 Regulation of cytochrome P450 2 (CYP2) by constitutive androstane 
receptor (CAR) 
CAR is a member of nuclear receptor superfamily. CAR is sequestered in the 
cytosol in a multi-protein complex which includes a recently identified protein 
termed CAR cytoplasmic retention protein (CCRP) and the Hsp90 (Figure 1.3) 
(Kobayashi et al., 2005, Timsit and Negishi, 2007). CAR is cytoplasmic in the 
dormant state and translocates to the nucleus upon activation by ligand. CAR can 
also be activated in a ligand-independent manner which does not necessarily require 
the direct binding of ligands (Honkakoski and Negishi, 2000). Phenobarbital and 
bilirubin have been shown to be CAR activators, but they do not appear to interact 
directly with the CAR-LBD (Moore et al., 2000b, Swales and Negishi, 2004). 
Activators can promote the nuclear translocation of CAR by a ligand-independent  
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Figure 1.3 CAR signalling pathway. CAR: Constitutive androstane receptor; 
PP2A: protein phosphatase 2a; Hsp20: heat shock protein 20; CCRP: 
CAR cytoplasmic retention protein; RXR: retinoic acid X receptor; 
RE: response element. (di Masi et al., 2009) 
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process, regardless of their receptor-binding ability (Waxman, 1999, di Masi et al., 
2009). Over expression of phosphatase 2A (PP2A) and mouse CAR enhances mouse 
CAR nuclear translocation in hepatoma cells. However, okadaic acid, a protein 
phosphatase inhibitor, blocks the phenobarbital-induced target gene expression in 
rodents (Sidhu and Omiecinski, 1997) and prevents nuclear accumulation of CAR 
(Honkakoski and Negishi, 1998).  
Translocation of CAR to the nucleus is followed by CAR association with 
another NR, retinoic acid X receptor (RXR) through heterodimerization forming 
CAR/RXR complex (di Masi et al., 2009, Waxman, 1999). CAR-DBD and RXR-
DBD heterodimerize in the ‘‘head-to-tail” orientation. The interaction between CAR-
DBD and RXR-DBD involves Tyr21, Asn24, and Asp79 of CAR-DBD and Arg172 
and Arg186 of RXR-DBD. CAR-DBD binds to the RE and recruitment of co-
activators such as apoptotic speck protein-2 (ASC-2), GRIP1/TIF2, PPAR gamma 
co-activator-1 (PGC-1), structural maintenance of chromosome-1 (SMC-1), and 
SRC-1 occurs leading to the expression of CYP2 (Kim et al., 1998, Muangmoonchai 
et al., 2001, Min et al., 2002a, Min et al., 2002b, Shiraki et al., 2003, Choi et al., 
2005, Inoue et al., 2006).   
 
1.2.4.3 Regulation of cytochrome P450 3 (CYP3) by pregnane-X receptor (PXR)  
PXR is also a member of nuclear receptor superfamily and appears to be 
located in the cytosol in the resting state, and the AF-2 region appears to be involved 
in pregnenolone 16α-carbonitrile-induced nuclear translocation (Matias et al., 2000). 
Like CAR, PXR forms a protein complex with CCRP and Hsp90 which, in turn, 
increase the cytosolic retention of PXR (Figure 1.4) (Squires et al., 2004). Upon  
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Figure 1.4 PXR signalling pathway. PXR: pregnane X receptor; PKA: protein 
kinase A; Hsp20: heat shock protein 20; CCRP: CAR cytoplasmic 
retention protein; RXR: retinoic acid X receptor; RE: response 
element. (Honkakoski and Negishi, 2000)  
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ligand binding, the PXR dissociates from the multi-protein complex and translocates 
to the nucleus to activate gene transcription as a heterodimer with RXR (Goodwin et 
al., 1999, Frank et al., 2005). Activation of PXR by ligands could result in the 
dissociation of co-repressors, such as the SMRT and NCoR, allowing the binding of 
the co-activators glucocorticoid receptor-interacting protein (GRIP) and SRC-1. 
While SMRT and NcoR stabilize chromatin and consequently repress transcription, 
SRC-1 and GRIP destabilize chromatin allowing the transcription machinery 
recruitment on DNA (Harmsen et al., 2007).  
Increased transcription is mediated by recruitment of the p160 family co-
activators, SRC-1, GRIP, PPAR-binding protein (PBP), and proliferator-activated 
receptors γ (PPARγ) coactivator-1 α (PGC-1α) (Ding and Staudinger, 2005a, Orans 
et al., 2005). On the other hand, the PXR transcriptional activity is inhibited by 
interactions with co-repressors including NCoR, RIP140, short heterodimer partner 
(SHP), and SMRT (Orans et al., 2005). PXR can be phosphorylated by protein kinase 
A (PKA), resulting in strengthened interaction with co-activators, such as SRC-1 and 
PBP (Ding and Staudinger, 2005a). In contrast, the activity of PXR can be repressed 
by the activation of protein kinase C α (PKCα) which alters the phosphorylation 
status of PXR and/or PXR-interacting proteins (i.e.,co-activators) (Ding and 
Staudinger, 2005a). In addition, okadaic acid, a protein phosphatase inhibitor, 
strongly represses PXR transactivation (Ding and Staudinger, 2005b). 
In fact, the regulation of CYP expressions are found to be more complicated 
as cross-talk among NRs occurred (Honkakoski and Negishi, 2000).  CYP-regulatory 
NRs belong to the same NR gene family (family NR1), share a common 
heterodimerization partner, retinoid X-receptor (RXR), and are subject to cross-talk 
interactions with other nuclear receptors and with a broad range of other intracellular 
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signalling pathways, including those activated by certain cytokines and growth 
factors (Honkakoski and Negishi, 2000, Waxman, 1999). These NRs include CAR, 
PXR, and PPAR. In man, PXR mediates xenobiotic-mediated induction of CYP3A4 
(Bertilsson et al., 1998, Blumberg et al., 1998, Lehmann et al., 1998), CYP3A7 
(Bertilsson et al., 2001, Pascussi et al., 1999), and CYP2B6 (Goodwin et al., 2001). 
Some reports suggest that CYP2C8 and CYP2C9 are also regulated by PXR (Gerbal-
Chaloin et al., 2002, Gerbal-Chaloin et al., 2001, Synold et al., 2001). Thus, PXR 
coordinately regulates genes involved in the metabolism and elimination of 
potentially harmful xenobiotics. PXR interacts with its cognate response elements in 
the 5’-flanking region of target genes by forming a heterodimer with the 9-cis-
retinoid acid receptor (RXR). In rat CYP3A23 and human CYP3A4, these elements 
consist of two copies of the AG(G/T)TCA hexanucleotide organized as a direct 
repeat with a three-nucleotide spacer and an everted repeat separated by 6 bp 
respectively. It is reported that these cognate response elements are also recognized 
by CAR (Sueyoshi et al., 1999) and vitamin D receptor (VDR) (Drocourt et al., 2002, 
Thummel et al., 2001) after heterodimerization with RXR. These observations 
suggest that these receptors are capable of regulating a same series of genes through 
the same cis-acting elements. 
 
1.2.4.4 Regulation of cytochrome P450 1 (CYP1) by aryl hydrocarbon receptors 
(AhR) 
Unlike CAR and PXR, aryl hydrocarbon receptor (AhR), a member of the 
basic-helix-loop-helix (bHLH)–Per-ARNT-Sim (PAS) gene superfamily, is a ligand-
activated transcription factor that functions as an intracellular mediator in the 
xenobiotic signalling pathway (Hahn, 2002). Normally, AhR exists in a dormant 
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state within the cytoplasm in association with a complex of heat shock protein 90 
(Hsp90), X-associated protein (XAP2), and 23-kDa heat shock protein (p23) (Figure 
1.5). Upon ligand binding, AhR in the complex is activated by a conformation 
change that exposes a nuclear localization signal (NLS). 2’,3’,7’,8’-
Tetrachlorodibenzo-p-dioxin (TCDD) and indolo [2,3-b] carbazole (ICZ) are the 
most potent inducers of CYP1 expression (Fujii-Kuriyama and Mimura, 2005, 
Kawajiri and Fujii-Kuriyama, 2007). The ligand-activated AhR in the complex 
translocates into the nucleus and forms a heterodimer with the closely related Arnt 
protein already present in the nucleus by dissociating from the complex (Mimura and 
Fujii-Kuriyama, 2003, Hankinson, 1995).  
However, it is also reported that AhR is activated in the absence of obvious 
ligands in Hepa 1clc7 cells (Sadek and Allen-Hoffmann, 1994b), human 
keratinocytes (Sadek and Allen-Hoffmann, 1994a), 10T1/2 fibroblasts (Cho et al., 
2004), and HaCaT cells (Ikuta et al., 2004) grown under specific culture conditions 
such as loss of cell-cell contact, low cell densities, and in Ca2+-deficient medium. 
Under such specific culture condition, the expression of AhR-responsive reporter is 
activated and further induces the nuclear accumulation of AhR (Cho et al., 2004). 
The nuclear accumulation of AhR is regulated by the phosphorylation of Ser68 
within the nuclear export sequence (NES) of AhR (Ikuta et al., 2004). Tyr320 is 
another putative phosphorylation site on AhR activated by omeprazole in a ligand-
independent manner via a signal transduction pathway that involves protein tyrosine 
kinases (Backlund and Ingelman-Sundberg, 2005). This pathway is independent from 
that induced by high-affinity ligands, such as TCDD. Although the protein kinases 
involved remain unclear, AhR can be activated in a ligand-independent manner. 
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Figure 1.5 AhR signalling pathway. AhR: aryl hydrocarbon receptor; p23: 23-
kDa heat shock protein; Hsp20: heat shock protein 90; XAP2: X-
associated protein; Arnt: aryl hydrocarbon receptor nuclear 
translocator; RE: response element (Fujii-Kuriyama and Mimura, 
2005).  
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The TCDD-induced expression of CYP1A1 is mediated through the RE 
(Fujisawa-Sehara et al., 1987). The core consensus sequence of RE is 5’-
TNGCGTG-3’, and this site is recognized by the AhR/Arnt heterodimer. 
Approximately 1 kb upstream of the CYP1A1 gene, a cluster of REs functions as an 
enhancer element, and a basic transcription element (BTE), a GC box sequence 
localized to the proximal promoter of CYP1A1, is also required for the induction of 
CYP1A1 (Kobayashi et al., 1996). Chromatin re-modelling is initiated by liganded 
AhR/Arnt heterodimer binding to the REs in the enhancer region, and this leads to 
increased DNase sensitivity and the appearance of a DNase hypersensitive site within 
300bp upstream of the transcription initiation site. The AhR/Arnt heterodimer 
transactivates in conjunction with general transcription factors (GTFs) through 
interactions with coactivator proteins including CREB binding protein/ E1A binding 
protein p300 (CBP/p300), SRC-1, NCoA-2 and p300/CBP/cointegrator-associated 
protein (p/CIP), and the coactivator/corepressor protein, receptor interacting protein 
140 (RIP140) (Beischlag et al., 2002).  
However, less is known about the factors regulating the induction of 
CYP1A2 expression, although the AhR/Arnt heterodimer is clearly required for 
induction to occur. One study suggests that the AhR/Arnt heterodimer may function 
as a coactivator without directly binding the RE. Instead, it may interact with other 
DNA-binding factors of a novel xenobiotic responsive element termed XREII to 
induce transcription activation (Sogawa et al., 2004).  
AhR is rapidly degraded both in vivo and in vitro following ligand binding 
and several studies have examined the regulation of AhR degradation (Fujii-
Kuriyama and Mimura, 2005, Kawajiri and Fujii-Kuriyama, 2007). When AhR is 
fused to the heterologous NLS of nucleoplasmin, it constitutively accumulates in the 
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nucleus and is degraded in a 26S proteasome-dependent manner (Roberts and 
Whitelaw, 1999). Conversely, when nuclear export of AhR is blocked by leptomycin 
B, AhR accumulates in the nucleus following ligand binding and is not efficiently 
degraded. In this system, AhR degradation requires both an NES and redistribution 
from the nucleus to the cytoplasm (Davarinos and Pollenz, 1999). 
The AhR repressor (AhRR) is identified as a negative regulator of AhR 
activity. AhRR contains both NLS and NES that are homologous to AhR, but AhRR 
is localized constitutively to the nucleus (Fujii-Kuriyama and Mimura, 2005, 
Kawajiri and Fujii-Kuriyama, 2007). Here, AhRR forms a heterodimer with Arnt, but 
RE binding by the AhRR/Arnt heterodimer leads to transcriptional repression. 
Finally, AhRR expression is induced in an AhR dependent manner, indicating that 
AhR and AhRR form a regulatory feedback loop (Mimura et al., 1999). 
 
1.2.5 The role of cytochromes P450 in drug interactions 
CYP enzymes are found to be involved in metabolism of 90% drugs available 
in the market nowadays (Lynch and Price, 2007).  During this process, drugs are 
metabolized and transformed into new chemical entities that may have either toxic or 
therapeutic effects. The pharmacological effects of a drug are basically based on the 
result of its effective interaction with the target which is concentration-dependent. 
Pharmacokinetics (absorption, distribution, metabolism, and excretion) of the 
compound also play a key role in its efficacy as it governs the drug concentration at 
the site of action (Donato et al., 2008). Inappropriate pharmacokinetics can result in 
an inadequate or variable concentration of the drug at the site of action and 
contribute to great variations in clinical response.  
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Drug metabolism is a major determinant of drug clearance and inter-
individual pharmacokinetic differences, and it is an indirect determinant of clinical 
efficacy and toxicity of drugs (Donato et al., 2008). Thus, many drug interactions are 
the result of an alteration of CYP metabolism. Basically, drug interactions involving 
the CYP enzymes are divided into two types: CYP enzyme induction or CYP 
enzyme inhibition. Common substrates, inhibitors and inducers of CYP enzymes are 
listed in Table 1.3.  
 
1.2.5.1 Induction of cytochromes P450  
 When CYP metabolism is enhanced by inducer, the effect of induction will 
increase the amount of CYP enzyme present and accelerate the rate of oxidation and 
clearance of another drug (Bibi, 2008). CYP induction is a slow regulatory process 
that reduces drug concentrations in plasma and compromise the efficacy of the drug 
in a time-dependent manner (Pelkonen et al., 2008). In most cases, induction of CYP 
enzymes is mediated to a major extent by group of nuclear receptor (NR) as 
discussed in the previous section (Pelkonen et al., 2008). For example, St John’s wort 
is a potent inducer of CYP3A4 and is involved in the most severe drug-herb 
interactions (Ernst, 1999, Moore et al., 2000a). Thus, the protease inhibitors, 
cyclosporine, warfarin, digoxin, oral contraceptives, and many other medications can 
be rendered ineffective with concomitant use of St John’s wort. CYP induction 
causes in a reduction of pharmacological effects caused by an increased in drug 
metabolism. 
 
 
 
